Shasun Pharmaceuticals has received another setback during the third quarter ended December 2010 and it net loss went up to Rs.9.66 crore from Rs.2.12 crore in the corresponding period of last year. Its net sales also declined by 6.1 per cent to Rs.195.26 crore from Rs.207.90 crore. Its EBDITA declined to Rs.6.78 crore from Rs.13.88 in the last period. The company has increased the production capacity of one of its main API products by 50 per cent during the quarter under review and validated one new product in formulation. It has undertaken capacity expansion of formulation facility in two phases to take advantage of growth opportunities.


Its UK based subsidiary posted turnover of Rs.49.16 crore and a loss of Rs.8.45 crore compared to turnover of Rs.65.18 crore and loss of Rs.8.97 crore mainly due to delays in customer supplied raw materials.


For the nine months ended December 2010, Shasun's net loss increased to Rs.11.80 crore from Rs.6.31 crore. Its net sales, however, increased to Rs.600.42 crore from Rs.575.58 crore, a growth of 4.3 per cent.